[논문]Pharmacodynamic comparison of acarbose tablets in Chinese healthy volunteers under chewing and swallowing conditions

Ji, Wei; Yang, Shaomei; Zhang, Wenyu; Sun, Zhongliang; Wen, Qing; He, Kun

doi:10.1111/jcpt.13361

Pharmacodynamic comparison of acarbose tablets in Chinese healthy volunteers under chewing and swallowing conditions 원문보기

Journal of clinical pharmacy and therapeutics, v.46 no.3, 2021년, pp.814 - 819

Ji, Wei (Department of Clinical Research Center, Jinan Central Hospital Affiliated to Shandong University, Jinan, China) , Yang, Shaomei (Department of Clinical Research Center, Jinan Central Hospital Affiliated to Shandong University, Jinan, China) , Zhang, Wenyu (Department of Clinical Research Center, Jinan Central Hospital Affiliated to Shandong University, Jinan, China) , Sun, Zhongliang (Shanghai LingXian Medical Consulting CO., LTD, Jinan, China) , Wen, Qing (Department of Clinical Research Center, Jinan Central Hospital Affiliated to Shandong University, Jinan, China) , He, Kun (Department of Clinical Research Center, Jinan Central Hospital Affiliated to Shandong University, Jinan, China)

Abstract ▼ AI-Helper

AbstractWhat is known and objectiveAcarbose can efficiently block glucose absorption in the intestine as an alpha‐glucosidase inhibitor. It is currently manufactured in several oral dosage forms, with the most common types being tablets and chewable tablets. The acarbose tablet (Glucobay®, 50 mg, Bayer) package insert gives instructions for either directly swallowing or chewing then swallowing. This study compared the pharmacodynamic effects of a single formulation of acarbose tablets under these two different administration routes.MethodsThis randomized, crossover study enrolled 24 healthy subjects who were instructed to chew (C group) or swallow (S group) the acarbose tablet. Glucose levels were monitored in subjects for up to 4 h following administration of 75 g of sucrose to establish a baseline firstly, after which subjects in the C and S groups were administered 50‐ or 100‐ mg of acarbose along with 75 g of sucrose. Then, subjects entered a 1‐week washout period before being crossed over to the alternate dosing route.Results and discussionCompared with the S group, the C group had a lower maximum concentration of serum glucose (Cmax) and areas under the concentration–time curve (AUC0‐2, AUC0‐1.5). In addition, the maximum reduction in serum glucose (ΔCmax) and the reduction in the AUC (AUEC0‐1.5) were both increased in the S group. This occurred at both the 50 mg and 100 mg dosages. These results indicate that fluctuations in blood glucose were lower following chewing of the acarbose tablet. Both administration routes exhibited similar safety and tolerance profiles.What is new and conclusionIn summary, chewing acarbose tablets appears to induce a superior glycaemic‐controlling effect compared with swallowing them directly, at least with a single dose. It will be important to inform both clinicians and patients about these differences between the two administrations so that informed clinical decisions can be made, as numerous patients with diabetes are inclined to directly swallow acarbose tablets for convenience.

주제어

참고문헌 (14)

Zhang, Min, Yang, Jin, Tao, Lei, Li, Lingjun, Ma, Pengcheng, Fawcett, John Paul. Acarbose Bioequivalence: Exploration of New Pharmacodynamic Parameters. The AAPS journal, vol.14, no.2, 345-351.

상세보기
Jiang, Jiebing, Li, Jiajia, Zhu, Jinglin, Yu, Yingjia, Duan, Gengli, Zhou, Ligang, Li, Yan. Synthesis of sandwich-structured magnetic graphene-Zn-MOFs composites for quantitative determination of acarbose in rat plasma. Talanta, vol.209, 120514-.

상세보기
Fang, Hui, Xu, Fengmei, Du, Jin, Liang, Li, Li, Wei, Shen, Liya, Wang, Xueying, Xu, Chun, Bian, Fang, Mu, Yiming. Impact of baseline characteristics on glycemic effects of add‐on saxagliptin or acarbose to metformin therapy: Subgroup analysis of the SMART study in Chinese patients with type 2 diabetes mellitus. Journal of diabetes investigation, vol.11, no.4, 896-905.

상세보기
Pishdad, Reza, Pishdad, Parisa, Pishdad, Gholam Reza. Acarbose versus Repaglinide in Diabetes Treatment: A New Appraisal of Two Old Rivals. The American journal of the medical sciences, vol.359, no.4, 212-217.

상세보기
Ghabi, Ameni, Brahmi, Jihed, Alminderej, Fahad, Messaoudi, Sabri, Vidal, Sébastien, Kadri, Adel, Aouadi, Kaïss. Multifunctional isoxazolidine derivatives as α-amylase and α-glucosidase inhibitors. Bioorganic chemistry, vol.98, 103713-.

상세보기
Gerstein, Hertzel C., Coleman, Ruth L., Scott, Charles A.B., Xu, Shishi, Tuomilehto, Jaakko, Rydén, Lars, Holman, Rury R.. Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial. Diabetes care, vol.43, no.9, 2242-2247.

상세보기
Dodds, Sherry G., Parihar, Manish, Javors, Martin, Nie, Jia, Musi, Nicolas, Dave Sharp, Zelton, Hasty, Paul. Acarbose improved survival for Apc^+/Min mice. Aging cell, vol.19, no.2, e13088-.

상세보기
Hanefeld, Markolf, Schaper, Frank. Acarbose: oral antidiabetes drug with additional cardiovascular benefits. Expert review of cardiovascular therapy, vol.6, no.2, 153-163.

상세보기
Hanefeld, Markolf, Schaper, Frank, Koehler, Carsta. Effect of Acarbose on Vascular Disease in Patients with Abnormal Glucose Tolerance. Cardiovascular drugs and therapy, vol.22, no.3, 225-231.

상세보기
Wu, Qian Lin, Liu, Yu Ping, Lu, Ju Ming, Wang, Chang Jiang, Yang, Tao, Dong, Ji Xiang, Li, Cheng Jiang, Ma, Jian Hua, Xue, Yao Ming, Sun, Rui Hua, Wei, Dong, Tian, Hao Ming. Efficacy and safety of acarbose chewable tablet in patients with type 2 diabetes: a multicentre, randomized, double‐blinded, double‐dummy positive controlled trial. Journal of evidence-based medicine, vol.5, no.3, 134-138.

상세보기
Pharmazie Debeljak J 566 71 2016 Randomised, double blind, cross‐over, placebo and active controlled human pharmacodynamic study on the influence of silver fir wood extract (Belinal) on post‐prandial glycemic response

상세보기
Kim, S., Jang, I.‐J., Shin, D., Shin, D. S., Yoon, S., Lim, K. S., Yu, K.‐S., Li, J., Zhang, H., Liu, Y., Brendel, E., Blode, H., Wang, Y.. Investigation of bioequivalence of a new fixed‐dose combination of acarbose and metformin with the corresponding loose combination as well as the drug–drug interaction potential between both drugs in healthy adult male subjects. Journal of clinical pharmacy and therapeutics, vol.39, no.4, 424-431.

상세보기
Lee, S., Chung, J. Y., Hong, K. S., Yang, S.‐H., Byun, S.‐Y., Lim, H.‐S., Shin, S.‐G., Jang, I.‐J., Yu, K.‐S.. Pharmacodynamic comparison of two formulations of Acarbose 100‐mg tablets. Journal of clinical pharmacy and therapeutics, vol.37, no.5, 553-557.

상세보기
Food and Drug Administration (FDA).Guidance on Acarbose 2017. Available athttps://www.accessdata.fda.gov/drugsatfda_docs/psg/Acarbose_oral%20tablet_NDA%2020482_final%2008‐17.pdf. Accessed January 4 2021.

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증

Pharmacodynamic comparison of acarbose tablets in Chinese healthy volunteers under chewing and swallowing conditions 원문보기

Abstract ▼ AI-Helper

주제어

참고문헌 (14)

이 논문을 인용한 문헌

관련 콘텐츠

원문 보기

원문 URL 링크

이 논문과 함께 이용한 콘텐츠

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

선택된 텍스트